Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$7.70 USD
-0.30 (-3.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.68 -0.02 (-0.26%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.70 USD
-0.30 (-3.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.68 -0.02 (-0.26%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Zacks News
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -5.26% and 4.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
by Zacks Equity Research
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Applied Therapeutics Inc. (APLT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
by Zacks Equity Research
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement
by Zacks Equity Research
Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma
by Zacks Equity Research
Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
by Zacks Equity Research
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.
Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?
by Zacks Equity Research
With no stable stream of income, bluebird bio (BLUE) faces a severe cash crunch. Moreover, the FDA extending the review period of its two regulatory filings also adds fuel to this fire.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.
Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal
by Zacks Equity Research
Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
by Zacks Equity Research
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.
Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA
by Zacks Equity Research
Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA. Shares down.
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study
by Zacks Equity Research
Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).
Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal
by Zacks Equity Research
Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.